Geron (NASDAQ:GERN) Stock Falls 6% – Should You Sell?

Geron Corporation (NASDAQ:GERN)’s stock price fell 6% during mid-day trading on Wednesday. The stock traded as low as $1.16 and last traded at $1.1650. Approximately 3,871,784 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 13,533,929 shares. The stock had previously closed at $1.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $4.00.

Geron Stock Down 6.0%

The firm’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.40. The company has a debt-to-equity ratio of 0.55, a current ratio of 6.91 and a quick ratio of 5.16. The company has a market cap of $748.48 million, a price-to-earnings ratio of -10.59 and a beta of 0.61.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The company had revenue of $57.48 million for the quarter, compared to analyst estimates of $55.30 million. Geron had a negative return on equity of 24.48% and a negative net margin of 34.17%. Sell-side analysts forecast that Geron Corporation will post -0.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC bought a new position in shares of Geron during the second quarter worth about $25,000. LCM Capital Management Inc acquired a new stake in Geron in the third quarter worth $25,000. GTS Securities LLC increased its holdings in shares of Geron by 71.6% in the 2nd quarter. GTS Securities LLC now owns 23,772 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 9,921 shares during the period. OneDigital Investment Advisors LLC acquired a new stake in shares of Geron in the second quarter valued at approximately $38,000. Finally, Corient Private Wealth LP raised its stake in Geron by 218.7% during the 2nd quarter. Corient Private Wealth LP now owns 34,455 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 23,643 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

About Geron

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on developing and commercializing treatments for blood cancers and other serious hematologic disorders. Its lead product is Rytelo (imetelstat), a telomerase inhibitor designed to target malignant cells by interfering with telomere maintenance.

In 2024, the U.S. Food and Drug Administration approved Rytelo for adults with lower-risk myelodysplastic syndromes who require regular red blood cell transfusions and have not responded adequately to, or have lost response to, or are ineligible for, erythropoiesis-stimulating agents.